Skip to content

ASPE ASPEN NEUROSCIENCE INC

Follow

Common Stock, par value $0.0001 per share (common), issuer CIK 2124080

No 13F filer reports this security in the loaded quarters.

13D and 13G filers

Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.

Insider trades

The latest Form 4 transactions, non-derivative.
OwnerDateSharesPriceFiling
Hasnain Faheemdirector, officer (Executive Chair)2026-11-05+321,672 A$0Form 4

Events

  • ARCH Venture Fund X, L.P. and 12 other reporting persons reported 3,754,922 ASPE shares, 12.9% of the class, as of 2026-11-02, in a 13D filed 2026-11-09. 0001193125-26-454047

    Accepted , ingested
  • Hasnain Faheem acquired 321,672 ASPE shares on 2026-11-05, Form 4 filed 2026-11-09. 0001193125-26-453834

    Accepted , ingested
  • Frazier Life Sciences X, L.P. and 4 other reporting persons reported 1,674,321 ASPE shares, 5.8% of the class, as of 2026-11-02, in a 13G filed 2026-11-09. 0001231919-26-001553

    Accepted , ingested
  • ORBIMED ADVISORS LLC and 1 other reporting person reported 3,589,132 ASPE shares, 12.3% of the class, as of 2026-11-02, in a 13D filed 2026-11-06. 0000947871-26-000996

    Accepted , ingested
  • GILEAD SCIENCES, INC. reported 2,879,996 ASPE shares, 9.9% of the class, as of 2026-10-30, in a 13G filed 2026-11-06. 0001123292-26-001496

    Accepted , ingested
  • FMR LLC and 1 other reporting person reported 3,250,000 ASPE shares, 11.2% of the class, as of 2026-10-30, in a 13G filed 2026-11-06. 0000315066-26-002950

    Accepted , ingested
  • Qatar Investment Authority reported 1,933,330 ASPE shares, 6.7% of the class, as of 2026-10-30, in a 13G filed 2026-11-03. 0001441449-26-000011

    Accepted , ingested